Introduction
Held in Dublin in September 2000, the third international meeting of Innovators in Urology was a ®tting tribute to our new millennium, as young researchers and clinicians from all over the world came together to participate in this unique conference. A scienti®c committee of international repute once again produced a challenging programme of activities that allowed dynamic one-to-one interaction between attendees, which encouraged them to discuss and appraise their latest research ®ndings and cajoled them into expressing their own views on many controversial issues in the ®eld of prostate cancer.
What makes Innovators in Urology such a special and successful meeting is the mix of hugely talented individuals whose areas of research span the entire disease spectrum. This year, we welcomed delegates from 15 countries whose research interests include endocrine therapy, screening and early diagnosis, HDR brachytherapy, quality of life assessment, angiogenesis, alternative therapies, metastatic behaviour and nutritional interventions, to name but a few. This broad spread of research interests is re¯ected in this supplement, and it is easy to see that research of this quality will unquestionably lead to a better understanding of prostate cancer mechanisms and ultimately to improved clinical and quality of life outcomes for our patients.
From a basic science perspective, I was especially impressed with the quality of work relating to IGF-1 and its role in the development of hormone-refractory prostate cancer. I also believe we have made great progress at this meeting in understanding factors that regulate angiogenesis. Clinical researchers continue to seek more sensitive and reproducible ways of detecting early prostate cancer and I was encouraged by the ongoing work in Hamburg, Germany, looking at strategies to select patients for nerve sparing radical prostatectomy.
All these papers were selected on their scienti®c merit and on their obvious insight into our unresolved issues in prostate cancer. Today's young innovators will be tomorrow's world experts and I would like to personally thank all of this year's participants for their frank and energetic contributions to the meeting.
I would also like to thank AstraZeneca, on behalf of both delegates and faculty members for its unfailing support of this meeting and its continued and increasing commitment to developing new treatments for prostate and other cancers.
Until we meet again next year, let the innovators innovate F F F
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